Absolute lymphocyte count predicts overall survival in follicular lymphomas

被引：100

作者：

Siddiqui, Mustaqeem ^{[1
]}

Ristow, Kay ^{[1
]}

Markovic, Svetomir N. ^{[1
]}

Witzig, Thomas E. ^{[1
]}

Habermann, Thomas M. ^{[1
]}

Colgan, Joseph P. ^{[1
]}

Inwards, David J. ^{[1
]}

White, William L. ^{[1
]}

Ansell, Stephen M. ^{[1
]}

Micallef, Ivana N. ^{[1
]}

Johnston, Patrick B. ^{[1
]}

Call, Timothy G. ^{[1
]}

Porrata, Luis F. ^{[1
]}

机构：

[1] Mayo Clin Rochester, Coll Med, Div Hematol, Dept Med, Rochester, MN USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 134卷 / 06期

关键词：

absolute lymphocyte count; follicular (grades 1 and 2) lymphomas; Follicular Lymphoma International Prognostic Index; survival;

D O I：

10.1111/j.1365-2141.2006.06232.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The peripheral blood absolute lymphocyte count (ALC) recovery after autologous stem cell transplantation has been shown to be an independent prognostic factor for survival for different haematologic malignancies. The role of ALC at diagnosis for follicular (grades 1 and 2) lymphomas (FL) on survival is not well described. The primary objective of this study was to assess the role of ALC on overall survival (OS) in FL patients. Of 1104 FL patients, 228 patients were originally diagnosed, followed, and had all treatment at the Mayo Clinic from 1984 and 1999, were evaluated. The median follow- up was 89 months (range: 8.35-248). ALC as a continuous variable was identified as a predictor for OS [Hazard ratio (HR) 0 74, P < 0 04]. ALC >= 1.0 x 10(9)/l (n = 164) predicted a longer OS versus ALC < 1.0 x 10(9)/l (n = 64; 175 vs. 73 months respectively, P < 0 0001). When compared with the Follicular Lymphoma International Prognostic Index (FLIPI), ALC was an independent prognostic factor for OS by multivariate analysis (HR = 0.677, P < 0 0001). These data suggest a critical role of FL patients' immune status at diagnosis on survival.

引用

页码：596 / 601

页数：6

共 24 条

[1] FOLLICULAR LARGE-CELL LYMPHOMA - INTERMEDIATE OR LOW-GRADE [J].

BARTLETT, NL ;

RIZEQ, M ;

DORFMAN, RF ;

HALPERN, J ;

HORNING, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) :1349-1357

[2] Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia [J].

Behl, D ;

Porrata, LF ;

Markovic, SN ;

Letendre, L ;

Pruthi, RK ;

Hook, CC ;

Tefferi, A ;

Elliot, MA ;

Kaufmann, SH ;

Mesa, RA ;

Litzow, MR .

LEUKEMIA, 2006, 20 (01) :29-34

[3] FACTORS PREDICTING FOR RESPONSE AND SURVIVAL IN ADULTS WITH ADVANCED NON-HODGKINS LYMPHOMA [J].

CABANILLAS, F ;

BURKE, JS ;

SMITH, TL ;

MOON, TE ;

BUTLER, JJ ;

RODRIGUEZ, V .

ARCHIVES OF INTERNAL MEDICINE, 1978, 138 (03) :413-418

[4] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[5]

COX DR, 1972, J R STAT SOC B, V34, P187

[6]

Ferrandina G, 2003, CLIN CANCER RES, V9, P195

[7]

Filipski E, 2002, J NATL CANCER I, V94, P690

[8] Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma [J].

Gordan, LN ;

Sugrue, MW ;

Lynch, JW ;

Williams, KD ;

Khan, SA ;

Moreb, JS .

BONE MARROW TRANSPLANTATION, 2003, 31 (11) :1009-1013

[9]

HORNING SJ, 1993, SEMIN ONCOL, V20, P75

[10] 131I-tositumomab therapy as initial treatment for follicular lymphoma [J].

Kaminski, MS ;

Tuck, M ;

Estes, J ;

Kolstad, A ;

Ross, CW ;

Zasadny, K ;

Regan, D ;

Kison, P ;

Fisher, S ;

Kroll, S ;

Wahl, RL .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (05) :441-449

← 1 2 3 →